# FDA recall D-0113-2026

> **QuVa Pharma, Inc.** · Class II · drug recall initiated 2025-10-10.

## Product

R.E.C.K. (Ropivacaine HCl, EPINEPHrine, CloNIDine HCl, and Ketorolac Tromethamine) in Sodium Chloride Solution, Total Volume: 50 mL syringe. INJECTION FOR PERIARTICULAR USE; Not for IV Use.  THIS IS A COMPOUNDED DRUG.  QuVA Pharma, 1075 West Park One Drive, Suite 100, Sugar Land, TX 77478.   NDC 70092-1433-50

## Reason for recall

Presence of Particulate Matter

## Distribution

U.S. Nationwide

## Key facts

- **Recall number:** D-0113-2026
- **Recalling firm:** QuVa Pharma, Inc.
- **Classification:** Class II
- **Product type:** drug
- **Status:** Ongoing
- **Initiation date:** 2025-10-10
- **Report date:** 2025-11-05

- **Voluntary/Mandated:** Voluntary: Firm initiated
- **Location:** Sugar Land, TX, United States

## Primary source

FDA Enforcement Reports: https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0113-2026

## Citation

> AI Analytics. FDA recall D-0113-2026. Retrieved 2026-07-02 from https://api.ai-analytics.org/recall/D-0113-2026. Source: US FDA. Licensed CC0.

---

*[Dataset catalog](/datasets/) · [FDA recalls dataset](/datasets/fda-recalls) · CC0 1.0*